LG Chem partners with UK's LabGenius on AI cancer drugs
Summary
LG Chem entered a joint research and license option agreement with UK biotech LabGenius to develop next-generation antibody therapies for cancer. The deal combines LabGenius’ AI-powered EVA platform with LG Chem’s drug development efforts to speed antibody discovery and improve candidate selection. LG Chem will pay upfront funding and support research during the collaboration, then decide later whether to license programs based on pre-agreed criteria. The company is also expanding its own AI drug development capabilities through MediX and other open innovation partnerships.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected